Iron Chelation Enhances TAM and Triple-Negative Breast Cancer Cell Death
Technical Report,15 Sep 2017,14 Sep 2018
Sloan Kettering Institute for Cancer Research New York United States
Pagination or Media Count:
The goal of this study is to complete preclinical testing of Deferiprone DFP, an iron chelator in clinical use for nononcologic diseases. We propose to demonstrate the sensitivity of TNBC to DFP as a single agent, and in combination with immune modulation therapy checkpoint inhibitors and chemotherapy paclitaxel. We will determine if imaging of changes in iron content using magnetic resonance imaging can serve as a biomarker of DFP efficacy. Studies were planned to be performed sequentially by first studying in vitro effects of DFP, followed by in vivo effects, followed by the effects of adding other drugs checkpoint inhibitors and paclitaxel. Effects of these drugs on cell cycle and immune effects were also proposed.
- Medicine and Medical Research